cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bellicum Pharmaceuticals Inc
31 own
51 watching
Current Price
$0.78
$0.02
(2.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
6.69M
52-Week High
52-Week High
1.55
52-Week Low
52-Week Low
0.2301
Average Volume
Average Volume
0.09M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
1.2551
iconMarket Capitalization6.69M
icon52-Week High1.55
icon52-Week Low0.2301
iconAverage Volume0.09M
iconDividend Yield--
iconP/E Ratio1.2551
What does the Bellicum Pharmaceuticals Inc do?
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company's preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. It has a collaboration agreement with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesu for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Read More
How much money does Bellicum Pharmaceuticals Inc make?
News & Events about Bellicum Pharmaceuticals Inc.
Globe Newswire
3 months ago
Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater responses in 50% of patients Responses observed in patients with visceral, nodal and bone involvement ...
Globe Newswire
4 months ago
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T product candidate, ...
Globe Newswire
5 months ago
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger...
Zolmax
10 months ago
StockNews.com initiated coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM Get Rating) in a report issued on Monday morning. The firm issued a sell rating on the biopharmaceutical companys stock. Separately, TheStreet downgraded shares of Bellicum Pharmaceuticals from a c- rating to a d- ...
Ticker Report
10 months ago
StockNews.com initiated coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM Get Rating) in a report published on Sunday. The firm issued a sell rating on the biopharmaceutical companys stock. Separately, TheStreet lowered shares of Bellicum Pharmaceuticals from a c- rating to ...
Frequently Asked Questions
Frequently Asked Questions
What is Bellicum Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Bellicum Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Bellicum Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Bellicum Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Bellicum Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Bellicum Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Bellicum Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Bellicum Pharmaceuticals Inc?
plus_minus_icon
What percentage is Bellicum Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Bellicum Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.78
$0.02
(2.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00